Sugi Predict

Sugi Predict / Compounds / SCHEMBL6623765

SCHEMBL6623765

SCHEMBL6623765

Cc1cc(-c2ccccn2)c(C)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.53
▸ METAP1 P53582 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ CCR1 P32246 2/20 0.46
▸ CCR5 P51681 2/20 0.46
▸ CCR8 P51685 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ DOHH Q9BU89 1/20 0.46
▸ P4HTM Q9NXG6 1/20 0.46
▸ NPC1 O15118 5/20 0.44
▸ CBFB Q13951 4/20 0.44
▸ METAP2 P50579 2/20 0.44
▸ OPRK1 P41145 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ RAB9A P51151 4/20 0.42
▸ PKM P14618 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6620993 0.78 CCR1 (0.57) KDM4EMETAP1CCR1CCR5CCR8
SCHEMBL9135350 0.77 KDM4E (0.49) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL11248052 0.77 PDE3B (0.60) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL11242781 0.77 CHEK1 (0.47) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL15450894 0.76 KDM4E (0.51) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL11246077 0.75 CHEK1 (0.48) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL1332803 0.74 KDM4E (0.53) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL8122697 0.74 CCR1 (0.54) CCR1CCR8NPC1METAP2RAB9A
SCHEMBL17427076 0.74 KDM4E (0.57) KDM4EMETAP1LMNACCR1CCR5
SCHEMBL5833033 0.73 KDM4E (0.34) KDM4ECCR1CCR8CYP1A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040229911-A1 New pharmaceutical combinations for NOS inhibitors PFIZER INC 2004-11-18 — — US disclosed
EP-1471055-A1 6-phenylpyridyl-2-amine derivatives PFIZER INC. (US) 2004-10-27 — — EP disclosed
US-20040142924-A1 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors PFIZER INC 2004-07-22 — — US disclosed
EP-0891332-B1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER (US) 2004-03-17 — — EP disclosed
EP-0946512-B1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER (US) 2003-10-08 — — EP disclosed
US-20020151572-A1 PHARMACEUTICAL USES FOR NOS INHIBITORS LOWE JOHN A (US) 2002-10-17 — — US disclosed
US-6465491-B2 NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS PFIZER INC. 2002-10-15 — — US disclosed
US-20020103227-A1 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors LOWE JOHN A (US) 2002-08-01 — — US disclosed
US-20020032191-A1 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors LOWE JOHN A (US) 2002-03-14 — — US disclosed
EP-1178784-A1 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS Pfizer Products Inc. (US) 2002-02-13 — — EP disclosed
US-20010034348-A1 6-phenylpyridyl-2-amine derivatives LOWE JOHN A (US) 2001-10-25 — — US disclosed
EP-1109556-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS Pfizer Products Inc. (US) 2001-06-27 — — EP disclosed
US-6235750-B1 NITRIC OXIDE SYNTHASE INHIBITOR PFIZER INC 2001-05-22 — — US disclosed
US-6235747-B1 NITRIC OXIDE SYNTHASE INHIBITOR PFIZER INC. 2001-05-22 — — US disclosed
WO-2000071107-A2 NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-11-30 — — WO disclosed
WO-2000009130-A2 NEW PHARMACEUTICAL USES FOR NOS INHIBITORS PFIZER PRODUCTS INC. (US) 2000-02-24 — — WO disclosed
EP-0946512-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER INC. (US) 1999-10-06 — — EP disclosed
EP-0891332-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1999-01-20 — — EP disclosed
WO-1998024766-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES USEFUL AS NOS INHIBITORS PFIZER INC. (US) 1998-06-11 — — WO disclosed
WO-1997036871-A1 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES PFIZER INC. (US) 1997-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034348-A1 6-phenylpyridyl-2-amine derivatives NOS2, NOS3, NOS1 KDM4E 1317/4885METAP1 1312/4885LMNA 2447/4885
US-20020151572-A1 PHARMACEUTICAL USES FOR NOS INHIBITORS NOS1, NOS3, NOS2 KDM4E 2697/4885METAP1 296/4885LMNA 2344/4885
US-20020032191-A1 6-phenylpyridyl-2-amine derivatives useful as NOS inhibitors NOS1, NOS2, NOS3 KDM4E 1439/4885METAP1 1098/4885LMNA 2947/4885
US-20040142924-A1 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors NOS1, NOS2, NOS3 KDM4E 1439/4885METAP1 1098/4885LMNA 2947/4885
US-20040229911-A1 New pharmaceutical combinations for NOS inhibitors NOS1, NOS3, NPBWR1 KDM4E 939/4885METAP1 2197/4885LMNA 3698/4885
US-20020103227-A1 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors NOS1, NOS2, NOS3 KDM4E 1439/4885METAP1 1098/4885LMNA 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.